Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

Neuroprotective Efficacy of ASO Therapies in a Rat Model of Amyotrophic Lateral Sclerosis (ALS)

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Neuroprotective Efficacy of ASO Therapies in a Rat Model of Amyotrophic Lateral Sclerosis (ALS)

Evaluating Neuroprotective Efficacy of ASO Therapies in Rat Models of ALS

CELL & GENE | RNA | BIOLOGICS

    What is the standard route of administration for ASOs in your ALS rat models?

    A: We primarily utilize intracerebroventricular (ICV) or intrathecal (IT) administration to ensure direct delivery to the central nervous system. The specific route is determined in consultation with the sponsor, based on the ASO’s mechanism of action and the program’s translational goals.

    Which specific rat model of ALS do you recommend for ASO efficacy studies?

    A: For therapies targeting superoxide dismutase 1, the SOD1-G93A transgenic rat model is the industry standard. It exhibits a predictable disease progression with measurable motor deficits, muscle atrophy, and motor neuron loss, providing robust endpoints for assessing therapeutic efficacy.

    What are the key functional endpoints measured in these studies?

    A: We assess motor function through a battery of tests including rotarod performance, grip strength analysis, and clinical scoring of motor deficits (e.g., hindlimb paralysis onset). These are correlated with survival and terminal histology endpoints.

    How do you ensure data integrity and reproducibility?

    A: All studies are conducted under GxP-compliant conditions within our >100,000 sq ft facility. We employ rigorous randomization, blinding during data acquisition and analysis, and standardized operating procedures to minimize variability and ensure the reliability of study outcomes.

Antisense oligonucleotide (ASO) therapies require preclinical models that accurately recapitulate key aspects of human amyotrophic lateral sclerosis (ALS) pathology. The SOD1-G93A rat model provides a robust platform for evaluating neuroprotective efficacy by measuring functional outcomes, survival, and target engagement. A successful study design integrates behavioral analysis with terminal histology and biomarker quantification to build a comprehensive data package, directly supporting an 18-24 month IND timeline.

ASO Efficacy Assessment in Progressive Neurodegeneration

Evaluating the therapeutic potential of an ASO targeting the root cause of a neurodegenerative disease demands a study design that can detect subtle changes in disease progression. In the context of ALS, this involves tracking the preservation of motor function and the delay of disease milestones. The primary objective is to generate definitive data on whether the therapeutic candidate can slow or halt the loss of motor neurons.

Our approach focuses on longitudinal functional assessments correlated with terminal molecular and histological endpoints. This methodology provides a clear, multi-faceted view of the ASO’s biological activity and therapeutic benefit.

A scientist in a lab coat and gloves looks through a microscope in a laboratory setting, with a blue color overlay.

A scientist pipetting a red liquid into a multi-well plate in a laboratory setting.

Strategic Model Selection and Endpoint Definition

The SOD1-G93A rat model is selected for its well-characterized and predictable disease course, which mirrors key features of familial ALS. This allows for statistically powered studies capable of detecting therapeutic effects against a consistent rate of decline.

Key study parameters include:

  • Functional Outcomes: Longitudinal monitoring of motor performance (rotarod, grip strength) and body weight provides objective measures of disease progression and therapeutic intervention.

  • Survival Analysis: Time to onset of end-stage paralysis is a primary endpoint, offering a clear measure of overall therapeutic benefit.

  • Terminal Analysis: We conduct post-mortem analysis of spinal cord and brain tissue to quantify motor neuron survival, assess glial activation, and measure target protein reduction (e.g., SOD1 aggregates).

Integrating Histology with Functional Data

Correlating functional improvements with underlying cellular changes provides a comprehensive assessment of therapeutic efficacy. To this end, we apply advanced histology techniques to quantify the extent of neuroprotection in the central nervous system.

By linking a delay in motor deficit onset to a statistically significant increase in surviving motor neurons in the lumbar spinal cord, we build a cohesive efficacy narrative. This rigorous approach has been a component of our strategy contributing to a 100% IND-enabling package success rate for programs initiated since 2019. (The Franklin Biolabs brand launched in 2024).

A female scientist in a lab coat analyzes complex biological data, including cellular imagery and DNA models, on a computer screen.

Animal Welfare and Programmatic Oversight

All in vivo studies are conducted in strict accordance with AAALAC and USDA guidelines. Our commitment to the 3Rs (Replacement, Reduction, and Refinement) is integrated into every study design. This includes using the minimum number of animals required for statistical power, refining procedures to minimize distress, and implementing humane endpoints. This ethical framework ensures the integrity and translatability of the data generated.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities